← Our writersEvidence & trials
Owen Castellanos
Reads the trial, not the landing page — and says plainly where a protocol has no evidence behind it.
Owen signs the research desk, covering the clinical literature on semaglutide, tirzepatide and the rest of the incretin class. That means what a trial was powered to show, what the effect sizes actually were, and the distance between a labeled dose and the protocols sold online. Every claim under this byline carries a citation you can open.
What they cover
- Semaglutide and tirzepatide clinical trials
- Incretin pharmacology and GLP-1 receptor agonism
- Dose titration schedules and tolerability
- Compounded versus FDA-approved drug regulation
- Evidence grading: human, animal, in-vitro
- Off-label and microdose prescribing evidence